As earnings season gains momentum, next week’s slate features heavyweights across tech, energy, industrials, and consumer sectors, offering a broad pulse on corporate health and macro conditions.

Tesla vs. BYD isn't much of a race in terms of EV sales. But TSLA stock is near a buy point. Earnings loom with robotaxis in focus on the call.

In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The company’s shares closed yesterday at CHF92.29. Evans ...